PrimeC
Sponsors
NeuroSense Therapeutics Ltd.
Conditions
ALSAlzheimer DiseaseAmyotrophic Lateral Sclerosis
Phase 2
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
CompletedNCT05357950
Start: 2022-05-31End: 2024-11-04Updated: 2025-09-05
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
TerminatedNCT06185543
Start: 2023-11-19End: 2025-09-30Updated: 2026-04-09